Pertuzumab is a recombinant humanized monoclonal antibody (mAb) and an important oncology biologic API used for targeting human epidermal growth factor receptor 2 (HER2). It is a humanized IgG1κ antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. Pertuzumab specifically recognizes subdomain II of the extracellular domain of HER2, also known as the receptor dimerization domain.
Pertuzumab is the active substance in Perjeta and is used in combination with other anticancer therapies for HER2-positive breast cancer. The European Medicines Agency classifies pertuzumab under antineoplastic monoclonal antibodies and antibody-drug-related therapies.
Pertuzumab has an approximate molecular weight of 148 kDa. The EMA characterization report provides a calculated molecular mass of 145,197 Da for the 448-residue heavy-chain form without heavy-chain glycosylation or C-terminal lysine; the fully glycosylated antibody has an approximate molecular mass of 148 kDa.
Pertuzumab consists of two heavy chains containing 449 amino acid residues each and two light chains containing 214 amino acid residues each. Each heavy chain contains an N-linked glycosylation site at Asn299.
Because pertuzumab is a complex recombinant protein, a simple small-molecule molecular formula is not an appropriate universal CMS identifier. Its characterization instead relies on amino-acid sequence, peptide mapping, mass spectrometry, glycosylation analysis and other orthogonal analytical methods.
Pertuzumab binds to HER2 subdomain II and prevents ligand-dependent dimerization of HER2 with other members of the HER receptor family, including EGFR, HER3 and HER4. This inhibits HER2-mediated intracellular signaling pathways involved in tumor-cell growth and survival. Pertuzumab can also contribute to antibody-dependent cell-mediated cytotoxicity (ADCC).
Pertuzumab has a complementary mechanism to trastuzumab because the two antibodies recognize different HER2 regions. This complementary HER2 blockade is an important feature of combination treatment for HER2-positive cancers.
Pertuzumab active substance is manufactured using a controlled recombinant CHO-cell process. The EMA describes a manufacturing process involving cell culture, harvest, protein recovery and purification, including affinity chromatography, low-pH viral inactivation, ion-exchange chromatography, virus filtration and ultrafiltration/diafiltration.
Quality control for pertuzumab requires biologic-specific analytical characterization. Important quality attributes include identity, protein concentration, purity, aggregation, molecular-size variants, charge variants, glycosylation, oxidation, deamidation, host-cell proteins, residual host-cell DNA, endotoxin and biological potency.
The EMA assessment report describes SE-HPLC, SDS-PAGE, peptide mapping and LC-MS among the analytical approaches used to characterize pertuzumab. A validated anti-proliferation assay based on HER2-expressing breast cancer cells is used for biological potency characterization and control.
Pertuzumab is primarily associated with HER2-positive oncology applications, particularly breast cancer. The EMA lists its use in metastatic, locally advanced, inflammatory and early-stage HER2-positive breast cancer in combination with trastuzumab and chemotherapy where appropriate.
As a biologic API, pertuzumab requires specialized manufacturing, storage and analytical controls. Conventional small-molecule specifications such as melting point, residue on ignition and specific rotation are not appropriate primary release attributes.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |